Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.
Number of employees : 275 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|T. Rowe Price Associates, Inc. (Investment Management) ||5,274,902||
|The Vanguard Group, Inc. ||4,066,312||
|Palo Alto Investors LP ||3,318,212||
|Eventide Asset Management LLC ||3,193,117||
|Foresite Capital Management LLC ||2,605,499||
|Fidelity Management & Research Co. LLC ||2,218,709||
|Goldman Sachs & Co. LLC (Private Banking) ||2,179,603||
|Alpine Associates Management, Inc. ||2,075,100||
|SSgA Funds Management, Inc. ||2,044,893||
|Fiera Capital Corp. (Investment Management) ||1,575,531||
|Company contact information|
Aimmune Therapeutics, Inc.
8000 Marina Boulevard
Brisbane, CA 94005-1884
Phone : +1.650.614.5220
Fax : +1.650.616.0075
Web : http://www.aimmune.com
Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
Sector Bio Therapeutic Drugs
Connections : Aimmune Therapeutics, Inc.